Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 63, Issue 4, 2011, Pages 904-913

  Audo, Rachel ^a   Calmon Hamaty, Flavia ^a   Baeten, Dominique ^b   Bruyer, Angelique ^a   Combe, Bernard ^a   Hahne, Michael ^a   Morel, Jacques ^c  

^a CNRS   (France)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYNOVIAL FLUID; SYNOVIOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; ARTHRITIS, RHEUMATOID; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOPROTEGERIN; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 79953678970     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30181     Document Type: Article

References (26)

1. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98.
2. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 2003;4:255-60. (Pubitemid 36322135)
3. Anel A, Bosque A, Naval J, Pineiro A, Larrad L, Alava MA, et al. Apo2L/TRAIL and immune regulation. Front Biosci 2007;12: 2074-84.
4. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. (Pubitemid 40852711)
5. Song K, Chen Y, Goke R, Wilmen A, Seidel C, Goke A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000;191:1095-104.
6. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005;280:15709-18. (Pubitemid 40616690)
7. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 2003;22:3842-52. (Pubitemid 36819657)
8. Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, et al. Tumor necrosis factor-related apoptosis-inducing ligandmediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 2005;65:7888-95. (Pubitemid 41297266)
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Van der Heijde D, Dankert T, Nieman F, Rau R, Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:941-7. (Pubitemid 29505074)
11. Audo R, Combe B, Coulet B, Morel J, Hahne M. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death Differ 2009;16:1227-37.
12. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
13. Terzioglu E, Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 2007;46:783-9. (Pubitemid 47061708)
14. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004;201:331-40. (Pubitemid 39453118)
15. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003;171:1061-9. (Pubitemid 36871423)
16. Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez de Ayala C, Martin-Mola E. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 2004;50:2786-93. (Pubitemid 39209515)
17. Martinez-Lorenzo MJ, Anel A, Saez-Gutierrez B, Royo-Canas M, Bosque A, Alava MA, et al. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol 2007;122:28-40. (Pubitemid 46026691)
18. Perlman H, Nguyen N, Liu H, Eslick J, Esser S, Walsh K, et al. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3. Arthritis Rheum 2003;48:3096-101. (Pubitemid 37409320)
19. Park YW, Ji JD, Lee JS, Ryang DW, Yoo DH. Actinomycin D renders cultured synovial fibroblasts susceptible to tumour necrosis factor related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Scand J Rheumatol 2003;32:356-63.
20. Jungel A, Baresova V, Ospelt C, Simmen BR, Michel BA, Gay RE, et al. Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 2006; 65:910-2.
21. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37. (Pubitemid 40315182)
22. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumorcell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7. (Pubitemid 47517508)
23. Castellino G, Corallini F, Trotta F, Secchiero P. Is there any role for tumour necrosis factor related apoptosis inducing ligandosteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis? Ann Rheum Dis 2008;67:1196-7.
24. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007;282:31601-9. (Pubitemid 350044899)
25. Martinez-Lorenzo MJ, Anel A, Saez-Gutierrez B, Royo-Canas M, Bosque A, Alava MA, et al. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol 2007;122:28-40. (Pubitemid 46026691)
26. Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, et al. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 2009;11:R13.